Related Experiment Video
Updated: Apr 23, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Alteronol induces differentiation of melanoma b16-f0 cells
Caixia Wang, Bo Zhang, Na Chen
1Binzhou Medical University, Yantai 264003, P.R. China. zqsyt@sohu.com.
Abstract:
Alteronol, isolated from microbial mutation strains, has been applied for Chinese and International patents for tumor treatment. The aim of this project study is to investigate characteristics of proliferation and redifferentiation induced by alteronol in B16-F0 mouse melanoma cells. Cell proliferation is determined by tetrazolium salt colorimetric method (MTT assay). Morphological changes were analyzed by using Giemsa staining. The levels of melanin and tyrosinase were measured by spectrophotometry. The mRNA expressions of tyrosinase-related protein Trp1 and Trp2 were evaluated by reverse transcription-polymerase chain reaction (RT-PCR). The anchorage-independent proliferation of B16-F0 was monitored by the colony formation assay. Tumorigenicity was characterized by an animal model in vivo. The results showed that the proliferation of B16-F0 cells was inhibited by alteronol in a concentration and time dependent manner. All well-known evaluation indexes of melanoma cell differentiation, including morphological changes and tyrosinase activity alteration, were greatly enhanced with the increase of alteronol concentrations. Taken together, the expression of tyrosinase related gene, decreased cell colony formation rate and the tumorigenicity in vivo; all of these revealed that alteronol plays a key role in inducing differentiation and suppressing the proliferation of B16-F0 tumor cells in vitro and in vivo.
Insights
Alteronol, derived from microbial strains, effectively suppresses melanoma cell proliferation and promotes differentiation. This compound shows promise in inhibiting tumor growth both in vitro and in vivo.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Alteronol is a compound derived from microbial mutation strains.
- It has potential applications in tumor treatment, with existing Chinese and International patents.
- B16-F0 mouse melanoma cells are a relevant model for studying melanoma progression.
Purpose of the Study:
- To investigate the effects of Alteronol on the proliferation and redifferentiation of B16-F0 mouse melanoma cells.
- To elucidate the mechanisms by which Alteronol influences melanoma cell characteristics.
- To evaluate the anti-tumorigenic potential of Alteronol.
Main Methods:
- Cell proliferation was assessed using the MTT assay.
- Morphological changes were analyzed via Giemsa staining.
- Melanin and tyrosinase levels were quantified spectrophotometrically.
- mRNA expression of tyrosinase-related proteins (Trp1, Trp2) was evaluated by RT-PCR.
- Colony formation assay monitored anchorage-independent proliferation.
- Tumorigenicity was assessed using an in vivo animal model.
Main Results:
- Alteronol inhibited B16-F0 cell proliferation in a concentration- and time-dependent manner.
- Melanoma cell differentiation markers, including morphology and tyrosinase activity, were significantly enhanced by Alteronol.
- Alteronol decreased colony formation rates and suppressed tumorigenicity in vivo.
- Expression of tyrosinase-related genes was modulated by Alteronol.
Conclusions:
- Alteronol effectively suppresses proliferation and induces differentiation in B16-F0 melanoma cells.
- The compound demonstrates anti-tumorigenic activity both in vitro and in vivo.
- Alteronol holds significant potential as a therapeutic agent for melanoma treatment.
